---
schema_version: "secwatch.filing_event.v1"
accession: "0001698530-24-000067"
form_type: "8-K"
ticker: "XCUR"
cik: "0001698530"
company_name: "EXICURE, INC."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:08:01.404052+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern

## Summary
- Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.
- Received $0.7M loan from DGP Co., Ltd. after May 31; 6% interest, 10-month maturity.
- Revenue of $0.5M from patent license for cavrotolimod (hepatitis) with private biopharma.
- Net loss improved to $0.8M from $4.4M YoY due to cost cuts and license revenue.
- Company states existing cash insufficient; substantial near-term financing needed.

## SEC filing metadata
- accession: 0001698530-24-000067
- form_type: 8-K
- ticker: XCUR
- cik: 0001698530
- company_name: EXICURE, INC.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1698530/000169853024000067/0001698530-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1698530/000169853024000067/xcur-20240617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001698530-24-000067
- JSON: https://secwatch.observer/filing/0001698530-24-000067.json
- Plain text: https://secwatch.observer/filing/0001698530-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.